FR15C0037I1 - - Google Patents
Info
- Publication number
- FR15C0037I1 FR15C0037I1 FR15C0037C FR15C0037I1 FR 15C0037 I1 FR15C0037 I1 FR 15C0037I1 FR 15C0037 C FR15C0037 C FR 15C0037C FR 15C0037 I1 FR15C0037 I1 FR 15C0037I1
- Authority
- FR
- France
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
- C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
- C08G65/32—Polymers modified by chemical after-treatment
- C08G65/329—Polymers modified by chemical after-treatment with organic compounds
- C08G65/337—Polymers modified by chemical after-treatment with organic compounds containing other elements
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/785—Polymers containing nitrogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
- C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
- C08G65/04—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring from cyclic ethers only
- C08G65/06—Cyclic ethers having no atoms other than carbon and hydrogen outside the ring
- C08G65/08—Saturated oxiranes
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
- C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
- C08G65/32—Polymers modified by chemical after-treatment
- C08G65/329—Polymers modified by chemical after-treatment with organic compounds
- C08G65/331—Polymers modified by chemical after-treatment with organic compounds containing oxygen
- C08G65/332—Polymers modified by chemical after-treatment with organic compounds containing oxygen containing carboxyl groups, or halides, or esters thereof
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
- C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
- C08G65/32—Polymers modified by chemical after-treatment
- C08G65/329—Polymers modified by chemical after-treatment with organic compounds
- C08G65/333—Polymers modified by chemical after-treatment with organic compounds containing nitrogen
- C08G65/33303—Polymers modified by chemical after-treatment with organic compounds containing nitrogen containing amino group
- C08G65/33317—Polymers modified by chemical after-treatment with organic compounds containing nitrogen containing amino group heterocyclic
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
- C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
- C08G65/32—Polymers modified by chemical after-treatment
- C08G65/329—Polymers modified by chemical after-treatment with organic compounds
- C08G65/333—Polymers modified by chemical after-treatment with organic compounds containing nitrogen
- C08G65/33396—Polymers modified by chemical after-treatment with organic compounds containing nitrogen having oxygen in addition to nitrogen
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L2203/00—Applications
- C08L2203/02—Applications for biomedical use
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Polymers & Plastics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Addiction (AREA)
- Hematology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Tropical Medicine & Parasitology (AREA)
- Oncology (AREA)
- Obesity (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Psychiatry (AREA)
- Communicable Diseases (AREA)
- Medicinal Preparation (AREA)
- Other Resins Obtained By Reactions Not Involving Carbon-To-Carbon Unsaturated Bonds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Polyethers (AREA)
- Detergent Compositions (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US53012203P | 2003-12-16 | 2003-12-16 | |
PCT/US2004/042661 WO2005058367A2 (en) | 2003-12-16 | 2004-12-16 | Pegylated small molecules |
Publications (2)
Publication Number | Publication Date |
---|---|
FR15C0037I1 true FR15C0037I1 (en) | 2015-06-26 |
FR15C0037I2 FR15C0037I2 (en) | 2016-09-30 |
Family
ID=34700098
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
FR15C0037C Active FR15C0037I2 (en) | 2003-12-16 | 2015-05-19 | SINGLE-DISPERSE COMPOSITIONS CONTAINING NALOXOL PEGYL |
Country Status (26)
Country | Link |
---|---|
US (2) | US7786133B2 (en) |
EP (3) | EP2604282B1 (en) |
JP (1) | JP4991312B2 (en) |
KR (1) | KR101168620B1 (en) |
CN (3) | CN102895666B (en) |
AU (2) | AU2004299138B2 (en) |
CA (2) | CA2758460C (en) |
CY (2) | CY1114992T1 (en) |
DK (1) | DK1694363T3 (en) |
EA (2) | EA015333B1 (en) |
ES (3) | ES2733764T3 (en) |
FR (1) | FR15C0037I2 (en) |
HK (2) | HK1146645A1 (en) |
HR (1) | HRP20140361T1 (en) |
HU (1) | HUS1500026I1 (en) |
IL (2) | IL176317A (en) |
LT (1) | LTC1694363I2 (en) |
LU (1) | LU92702I2 (en) |
NL (1) | NL300737I2 (en) |
NZ (3) | NZ583573A (en) |
PL (1) | PL1694363T3 (en) |
PT (1) | PT1694363E (en) |
RS (1) | RS53279B (en) |
SI (1) | SI1694363T1 (en) |
WO (1) | WO2005058367A2 (en) |
ZA (1) | ZA200605763B (en) |
Families Citing this family (103)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090143328A1 (en) * | 2001-08-13 | 2009-06-04 | Mcdonald George | Method of Treating Cancer by Administration of Topical Active Corticosteroids |
CA2463938C (en) | 2001-10-18 | 2011-08-09 | Nektar Therapeutics Al, Corporation | Polymer conjugates of opioid antagonists |
EP2604282B1 (en) | 2003-12-16 | 2019-06-19 | Nektar Therapeutics | Method for preparing of monodisperse oligo ethylene glycol |
US20060182692A1 (en) | 2003-12-16 | 2006-08-17 | Fishburn C S | Chemically modified small molecules |
EP2545933A3 (en) | 2006-01-05 | 2013-04-24 | University Of Utah Research Foundation | Methods and compositions related to improving properties of pharmacological agents targeting nervous system |
SI1988910T1 (en) | 2006-02-28 | 2018-02-28 | Kodiak Sciences Inc. | Acryloyloxyethylphosphorylcholine containing polymer conjugates and their preparation |
JP5586223B2 (en) * | 2006-04-21 | 2014-09-10 | ネクター セラピューティクス | Stereoselective reduction of morphinone. |
AU2007317788B2 (en) * | 2006-11-07 | 2013-05-02 | Nektar Therapeutics | Dosage forms and co-administration of an opioid agonist and an opioid antagonist |
KR100829890B1 (en) | 2007-02-08 | 2008-05-16 | 주식회사 바이오폴리메드 | Novel retinol derivatives, process for the preparation thereof and cosmetic composition comprising the same for improving wrinkle |
US10512644B2 (en) | 2007-03-12 | 2019-12-24 | Inheris Pharmaceuticals, Inc. | Oligomer-opioid agonist conjugates |
US8173666B2 (en) | 2007-03-12 | 2012-05-08 | Nektar Therapeutics | Oligomer-opioid agonist conjugates |
US8389759B2 (en) | 2007-03-12 | 2013-03-05 | Nektar Therapeutics | Oligomer-anticholinergic agent conjugates |
PT2134371E (en) * | 2007-03-12 | 2015-04-16 | Nektar Therapeutics | Oligomer-opioid agonist conjugates |
AU2014200906B2 (en) * | 2007-03-12 | 2016-07-07 | Nektar Therapeutics | Oligomer-protease inhibitor conjugates |
AU2008226791B2 (en) * | 2007-03-12 | 2014-01-16 | Nektar Therapeutics | Oligomer-antihistamine conjugates |
JP2010521465A (en) * | 2007-03-12 | 2010-06-24 | ネクター セラピューティックス | De novo synthesis of complex |
WO2008112289A2 (en) * | 2007-03-12 | 2008-09-18 | Nektar Therapeutics | Oligomer-protease inhibitor conjugates |
WO2008112287A1 (en) * | 2007-03-12 | 2008-09-18 | Nektar Therapeutics | Oligomer-beta blocker conjugates |
WO2009032286A2 (en) * | 2007-09-06 | 2009-03-12 | Nektar Therapeutics Al, Corporation | Oligomer-calcium channel blocker conjugates |
US8741858B2 (en) | 2007-09-21 | 2014-06-03 | Zhongxu Ren | Oligomer-nucleoside phosphate conjugates |
WO2009045539A2 (en) * | 2007-10-05 | 2009-04-09 | Nektar Therapeutics Al, Corporation | Oligomer-corticosteroid conjugates |
WO2009054916A2 (en) * | 2007-10-19 | 2009-04-30 | Nektar Therapeutics Al, Corporation | Oligomer conjugates of lidocaine and its derivatives |
WO2009058387A2 (en) | 2007-11-02 | 2009-05-07 | Nektar Therapeutics Al, Corporation | Oligomer-nitroimidazole anti-infective conjugates |
US8536213B2 (en) | 2007-11-16 | 2013-09-17 | Nektar Therapeutics | Oligomer-dantrolene conjugates and related compounds |
EP2222342B1 (en) * | 2007-11-28 | 2014-03-26 | Nektar Therapeutics | Oligomer-tricyclic conjugates |
WO2009089053A1 (en) * | 2008-01-11 | 2009-07-16 | Nektar Therapeutics Al, Corporation | Oligomer-guanidine class conjugates |
US8685979B2 (en) | 2008-01-25 | 2014-04-01 | Nektar Therapeutics | Oligomer-diarylpiperazine conjugates |
JP5704925B2 (en) * | 2008-02-08 | 2015-04-22 | ウェルズ ファーゴ バンク ナショナル アソシエイション | Oligomer-cannabinoid conjugate |
WO2009105258A1 (en) | 2008-02-22 | 2009-08-27 | Nektar Therapeutics Al, Corporation | Oligomer conjugates of heteropentacyclic nucleosides |
WO2009114151A1 (en) | 2008-03-12 | 2009-09-17 | Nektar Therapeutics | Oligomer-amino acid and olgomer-atazanavir conjugates |
US9006219B2 (en) | 2008-03-12 | 2015-04-14 | Nektar Therapeutics | Oligomer-foscarnet conjugates |
US20110059921A1 (en) * | 2008-03-27 | 2011-03-10 | Ektar Therapeutics | Oligomer-Nitrogenous Base Conjugates |
US9233165B2 (en) * | 2008-04-11 | 2016-01-12 | Nektar Therapeutics | Oligomer-aryloxy-substituted propanamine conjugates |
US9095621B2 (en) | 2008-04-25 | 2015-08-04 | Nektar Therapeutics | Oligome-bis-chromonyl compound conjugates |
KR20220035504A (en) | 2008-04-30 | 2022-03-22 | 이뮤노젠 아이엔씨 | Cross-linkers and their uses |
NZ589733A (en) * | 2008-05-07 | 2012-07-27 | Nektar Therapeutics | Oral administration of peripherally-acting opioid antagonists |
WO2009151590A2 (en) * | 2008-06-09 | 2009-12-17 | Nektar Therapeutics | Methods of treating cyp2d6 alternative metabolizers |
CN102159249A (en) * | 2008-09-16 | 2011-08-17 | 尼克塔治疗公司 | Pegylated opioids with low potential for abuse |
WO2010033219A2 (en) | 2008-09-17 | 2010-03-25 | Nektar Therapeutics | Protease inhibitors having enhanced features |
WO2010033226A1 (en) * | 2008-09-17 | 2010-03-25 | Nektar Therapeutics | Oligomer-protease inhibitor conjugates |
MX2011007940A (en) * | 2009-01-28 | 2011-08-15 | Nektar Therapeutics | Oligomer-phenothiazine conjugates. |
WO2010099200A1 (en) | 2009-02-24 | 2010-09-02 | Nektar Therapeutics | Oligomer-amino acid conjugates |
US8530492B2 (en) | 2009-04-17 | 2013-09-10 | Nektar Therapeutics | Oligomer-protein tyrosine kinase inhibitor conjugates |
US8816077B2 (en) | 2009-04-17 | 2014-08-26 | Nektar Therapeutics | Oligomer-protein tyrosine kinase inhibitor conjugates |
CA2760219C (en) | 2009-05-13 | 2016-08-16 | Nektar Therapeutics | Oligomer-containing substituted aromatic triazine compounds |
WO2010132693A2 (en) | 2009-05-13 | 2010-11-18 | Nektar Therapeutics | Oligomer-containing pyrrolidine compounds |
EP2437790B1 (en) | 2009-06-03 | 2019-02-20 | Immunogen, Inc. | Conjugation methods |
EP2440249A2 (en) | 2009-06-12 | 2012-04-18 | Nektar Therapeutics | Covalent conjugates comprising a protease inhibitor, a water-soluble, non-peptidic oligomer and a lipophilic moiety |
CN105503889B (en) * | 2009-07-21 | 2019-12-24 | 尼克塔治疗公司 | Oligomer-opioid agonist conjugates |
JP5837491B2 (en) | 2009-07-21 | 2015-12-24 | ウェルズ ファーゴ バンク ナショナル アソシエイション | Oligomer-opioid agonist conjugates |
US8722732B2 (en) | 2009-09-29 | 2014-05-13 | Nektar Therapeutics | Oligomer-calcimimetic conjugates and related compounds |
KR101828613B1 (en) * | 2009-09-29 | 2018-02-12 | 넥타르 테라퓨틱스 | Oligomer-calcimimetic conjugates and related compounds |
US8765432B2 (en) | 2009-12-18 | 2014-07-01 | Oligasis, Llc | Targeted drug phosphorylcholine polymer conjugates |
WO2011088140A1 (en) | 2010-01-12 | 2011-07-21 | Nektar Therapeutics | Pegylated opioids with low potential for abuse and side effects |
WO2011091050A1 (en) | 2010-01-19 | 2011-07-28 | Nektar Therapeutics | Oligomer-tricyclic conjugates |
US9226970B2 (en) * | 2010-02-22 | 2016-01-05 | Nektar Therapeutics | Oligomer modified diaromatic substituted compounds |
US20160015656A2 (en) * | 2010-08-05 | 2016-01-21 | Nitto Denko Corporation | Composition for regenerating normal tissue from fibrotic tissue |
UA112847C2 (en) * | 2010-09-30 | 2016-11-10 | Астразенека Аб | Oxalate Salt of mPEG7-O-Naloxol Conjugate (OPTIONS), METHOD OF PREPARATION (OPTIONS) AND PHARMACEUTICAL COMPOSITION |
WO2012051551A1 (en) | 2010-10-15 | 2012-04-19 | Nektar Therapeutics | N-optionally substituted aryl-2-oligomer-3-alkoxypropionamides |
EP2648707B1 (en) | 2010-12-10 | 2016-05-11 | Nektar Therapeutics | Hydroxylated tricyclic compounds |
WO2012082995A1 (en) | 2010-12-15 | 2012-06-21 | Nektar Therapeutics | Oligomer-containing hydantoin compounds |
EP2651429B1 (en) * | 2010-12-15 | 2018-03-28 | Neuroadjuvants, Inc. | Neuropeptide analogs, compositions, and methods for treating pain |
WO2012083153A1 (en) | 2010-12-16 | 2012-06-21 | Nektar Therapeutics | Oligomer-containing apremilast moiety compounds |
US9943605B2 (en) | 2010-12-23 | 2018-04-17 | Nektar Therapeutics | Polymer-semaxanib moiety conjugates |
US10525054B2 (en) | 2011-11-07 | 2020-01-07 | Inheris Biopharma, Inc. | Compositions, dosage forms, and co-administration of an opioid agonist compound and an analgesic compound |
CN103906522B (en) | 2011-11-07 | 2017-04-12 | 尼克塔治疗公司 | Compositions, dosage forms, and coadministration of opioid agonist compound and analgesic compound |
CN103289075B (en) * | 2012-02-22 | 2016-01-20 | 天津键凯科技有限公司 | The binding substances of polyoxyethylene glycol and naloxone and pharmaceutical composition thereof and application |
WO2014043707A1 (en) | 2012-09-17 | 2014-03-20 | Nektar Therapeutics | Oligomer-containing benzamide-based compounds |
WO2014080251A1 (en) | 2012-11-24 | 2014-05-30 | Hangzhou Dac Biotech Co., Ltd. | Hydrophilic linkers and their uses for conjugation of drugs to cell binding molecules |
CN104208715B (en) * | 2013-05-31 | 2016-12-28 | 天津键凯科技有限公司 | There is the medicine bioactive low molecular poly drug conjugates of raising |
US9789198B2 (en) * | 2013-05-31 | 2017-10-17 | Jenkem Technology Co., Ltd. (Tianjin) | Low molecular weight polyethylene glycol drug conjugates having improved drug biological activity |
WO2014210436A2 (en) | 2013-06-28 | 2014-12-31 | Nektar Therapeutics | Kappa opioid agonists and uses thereof |
US10702608B2 (en) | 2013-09-08 | 2020-07-07 | Kodiak Sciences Inc. | Factor VIII zwitterionic polymer conjugates |
WO2015079459A1 (en) | 2013-11-27 | 2015-06-04 | Nektar Therapeutics (India) Pvt.Ltd. | Opioid agonists and uses thereof |
WO2015095644A1 (en) | 2013-12-20 | 2015-06-25 | AntiOP, Inc. | Intranasal naloxone compositions and methods of making and using same |
WO2015127685A1 (en) | 2014-02-28 | 2015-09-03 | Hangzhou Dac Biotech Co., Ltd | Charged linkers and their uses for conjugation |
US9840553B2 (en) | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
WO2016004321A1 (en) * | 2014-07-03 | 2016-01-07 | Board Of Regents, The University Of Texas System | Compounds for treating biofilm infection |
KR20210013299A (en) | 2014-10-17 | 2021-02-03 | 코디악 사이언시스 인코포레이티드 | Butyrylcholinesterase zwitterionic polymer conjugates |
WO2016064914A1 (en) * | 2014-10-20 | 2016-04-28 | Elysium Therapeutics, Inc. | Diversion-resistant opioid formulations |
CN104473927A (en) * | 2014-12-05 | 2015-04-01 | 北京键凯科技有限公司 | Polyethylene glycol and medicine molecule conjugate and preparation method thereof |
JP6665189B2 (en) | 2014-12-23 | 2020-03-13 | ネクター セラピューティクス | N-methyl-N- (1-phenyl-2- (1-pyrrolidinyl) ethyl) -2-aminophenylacetamide derivative agonist for kappa opioid receptor |
WO2016164916A1 (en) | 2015-04-10 | 2016-10-13 | Thomas Jefferson University | Methods and compositions for treating cancers and enhancing therapeutic immunity by selectively reducing immunomodulatory m2 monocytes |
EP3294714B1 (en) | 2015-05-08 | 2023-03-15 | Nektar Therapeutics | Morphinan derivatives for the treatment of neuropathic pain |
WO2015151081A2 (en) | 2015-07-12 | 2015-10-08 | Suzhou M-Conj Biotech Co., Ltd | Bridge linkers for conjugation of a cell-binding molecule |
US9839687B2 (en) | 2015-07-15 | 2017-12-12 | Suzhou M-Conj Biotech Co., Ltd. | Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule |
KR20180104635A (en) | 2015-12-30 | 2018-09-21 | 코디악 사이언시스 인코포레이티드 | Antibodies and conjugates thereof |
CN107033154B (en) | 2016-02-02 | 2020-02-04 | 上海瀚迈生物医药科技有限公司 | Opioid receptor antagonist conjugates and uses thereof |
CN107033155B (en) * | 2016-02-04 | 2019-04-26 | 国药集团国瑞药业有限公司 | A kind of Stereoselective reduction method of morphine ketone compounds |
EP3228307A1 (en) | 2016-04-05 | 2017-10-11 | Sandoz Ag | Solid dispersion comprising opioid antagonists |
KR20220147720A (en) | 2016-11-14 | 2022-11-03 | 항저우 디에이씨 바이오테크 씨오, 엘티디 | Conjugation linkers, cell binding molecule-drug conjugates containing the likers, methods of making and uses such conjugates with the linkers |
EP3544590A4 (en) * | 2016-11-23 | 2020-10-28 | Aurobindo Pharma Limited | Naloxegol oxalate and solid dispersion thereof |
JP7022328B2 (en) | 2017-03-30 | 2022-02-18 | 日油株式会社 | Hydrophilic polymer derivative with self-destructive acetal linker and complex using it |
JP6990355B2 (en) | 2017-03-30 | 2022-01-12 | 日油株式会社 | Heterobifunctional monodisperse polyethylene glycol and complex using it |
CN109134479A (en) * | 2017-06-27 | 2019-01-04 | 石家庄蒎格医药科技有限公司 | Crystalline polyethylene glycol naloxone oxalates and preparation method |
WO2019058387A1 (en) * | 2017-09-19 | 2019-03-28 | Msn Laboratories Private Limited, R&D Center | An improved process for the preparation of (5α,6α)-17-allyl-6-(2,5,8,11,14,17,20- heptaoxadocosan-22-yloxy)-4,5-epoxymorphinan-3,14-diol and its pharmaceutically acceptable salts |
AU2019227997A1 (en) | 2018-03-02 | 2020-09-24 | Kodiak Sciences Inc. | IL-6 antibodies and fusion constructs and conjugates thereof |
KR102542988B1 (en) | 2018-03-13 | 2023-06-13 | 니치유 가부시키가이샤 | Heterobifunctional compound having monodisperse polyethylene glycol in main chain and side chain |
US20220362397A1 (en) | 2019-09-26 | 2022-11-17 | Nof Corporation | Heterobifunctional monodispersed polyethylene glycol having peptide linker |
EP4041312A4 (en) | 2019-10-10 | 2023-12-20 | Kodiak Sciences Inc. | Methods of treating an eye disorder |
CN113827576B (en) * | 2021-11-17 | 2023-08-01 | 北京尚修堂医药科技有限公司 | Pharmaceutical composition with naloxone oxalate as active ingredient and preparation method thereof |
IT202200026703A1 (en) | 2022-12-23 | 2024-06-23 | Sintalica S R L | Non-hallucinogenic tryptamine compounds, preparation, pharmaceutical compositions and their uses |
US20240288374A1 (en) | 2023-02-13 | 2024-08-29 | Zymeron Corporation | Plasmonic nanoparticle platform for analyte detection |
Family Cites Families (91)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4223163A (en) * | 1976-12-10 | 1980-09-16 | The Procter & Gamble Company | Process for making ethoxylated fatty alcohols with narrow polyethoxy chain distribution |
US4366159A (en) * | 1981-09-08 | 1982-12-28 | Michael Richard Magruder | Nalbuphine-narcotic analgesic composition and method of producing analgesia |
FR2514644A1 (en) * | 1981-10-19 | 1983-04-22 | Sanofi Sa | PHARMACEUTICAL COMPOSITION WITH PERIPHERAL ANTAGONIST ACTION OF OPIACES |
US4587046A (en) * | 1982-05-18 | 1986-05-06 | The Regents Of The University Of California | Drug-carrier conjugates |
EP0206448B1 (en) * | 1985-06-19 | 1990-11-14 | Ajinomoto Co., Inc. | Hemoglobin combined with a poly(alkylene oxide) |
US4730048A (en) * | 1985-12-12 | 1988-03-08 | Regents Of The University Of Minnesota | Gut-selective opiates |
US4806556A (en) * | 1985-12-12 | 1989-02-21 | Regents Of The University Of Minnesota | Gut-selective opiates |
US4719215A (en) * | 1986-03-07 | 1988-01-12 | University Of Chicago | Quaternary derivatives of noroxymorphone which relieve nausea and emesis |
US4861781A (en) * | 1986-03-07 | 1989-08-29 | The University Of Chicago | Quaternary derivatives of noroxymorphone which relieve nausea and emesis |
US4801575A (en) * | 1986-07-30 | 1989-01-31 | The Regents Of The University Of California | Chimeric peptides for neuropeptide delivery through the blood-brain barrier |
US5080891A (en) * | 1987-08-03 | 1992-01-14 | Ddi Pharmaceuticals, Inc. | Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols |
JPH01207320A (en) | 1988-02-15 | 1989-08-21 | Daicel Chem Ind Ltd | Production of aromatic polyether |
IT1216687B (en) * | 1988-04-01 | 1990-03-08 | Boehringer Biochemia Srl | PLATINUM (II) COMPLEXES, THEIR PREPARATION AND USE AS ANTI-CANCER PRODUCTS. |
US5102887A (en) * | 1989-02-17 | 1992-04-07 | Arch Development Corporation | Method for reducing emesis and nausea induced by the administration of an emesis causing agent |
DE69030829T2 (en) * | 1989-03-10 | 1998-01-15 | Hoffmann La Roche | Drugs for the detection of drugs |
US5324844A (en) * | 1989-04-19 | 1994-06-28 | Enzon, Inc. | Active carbonates of polyalkylene oxides for modification of polypeptides |
US5122614A (en) * | 1989-04-19 | 1992-06-16 | Enzon, Inc. | Active carbonates of polyalkylene oxides for modification of polypeptides |
JPH0383914A (en) * | 1989-08-18 | 1991-04-09 | W R Grace & Co | Drug carrier |
DE3937797A1 (en) * | 1989-11-14 | 1991-05-16 | Basf Ag | METHOD FOR PRODUCING POLYETHERGLYCOLES |
US5130126A (en) * | 1990-07-09 | 1992-07-14 | Nippon Oil & Fats Co., Ltd. | Polymer-drug conjugate and a method of producing it |
IE912365A1 (en) * | 1990-07-23 | 1992-01-29 | Zeneca Ltd | Continuous release pharmaceutical compositions |
JP2829794B2 (en) * | 1991-02-08 | 1998-12-02 | エスエス製薬 株式会社 | Orally administered pranoprofen formulation for sustained release |
US5270328A (en) | 1991-03-29 | 1993-12-14 | Eli Lilly And Company | Peripherally selective piperidine opioid antagonists |
US5159081A (en) * | 1991-03-29 | 1992-10-27 | Eli Lilly And Company | Intermediates of peripherally selective n-carbonyl-3,4,4-trisubstituted piperidine opioid antagonists |
US5250542A (en) | 1991-03-29 | 1993-10-05 | Eli Lilly And Company | Peripherally selective piperidine carboxylate opioid antagonists |
AU4406793A (en) | 1992-06-04 | 1993-12-30 | Clover Consolidated, Limited | Water-soluble polymeric carriers for drug delivery |
GB9316895D0 (en) * | 1993-08-13 | 1993-09-29 | Guy S And St Thomas Hospitals | Hepatoselective insulin analogues |
EP0599303A3 (en) * | 1992-11-27 | 1998-07-29 | Takeda Chemical Industries, Ltd. | Peptide conjugate |
US5298643A (en) * | 1992-12-22 | 1994-03-29 | Enzon, Inc. | Aryl imidate activated polyalkylene oxides |
US5321095A (en) * | 1993-02-02 | 1994-06-14 | Enzon, Inc. | Azlactone activated polyalkylene oxides |
US5298410A (en) * | 1993-02-25 | 1994-03-29 | Sterling Winthrop Inc. | Lyophilized formulation of polyethylene oxide modified proteins with increased shelf-life |
ES2122261T3 (en) * | 1993-03-17 | 1998-12-16 | Minnesota Mining & Mfg | AEROSOL FORMULATION CONTAINING A DISPERSION ADJUVANT DERIVED FROM AN ESTER, AMIDA OR MERCAPTOESTER. |
WO1995000162A1 (en) * | 1993-06-21 | 1995-01-05 | Enzon, Inc. | Site specific synthesis of conjugated peptides |
US5643575A (en) * | 1993-10-27 | 1997-07-01 | Enzon, Inc. | Non-antigenic branched polymer conjugates |
US5434171A (en) | 1993-12-08 | 1995-07-18 | Eli Lilly And Company | Preparation of 3,4,4-trisubstituted-piperidinyl-N-alkylcarboxylates and intermediates |
US5693609A (en) | 1994-11-17 | 1997-12-02 | Eli Lilly And Company | Acylated insulin analogs |
US5932462A (en) | 1995-01-10 | 1999-08-03 | Shearwater Polymers, Inc. | Multiarmed, monofunctional, polymer for coupling to molecules and surfaces |
US5670477A (en) * | 1995-04-20 | 1997-09-23 | Joseph F. Poduslo | Method to enhance permeability of the blood/brain blood/nerve bariers to therapeutic agents |
TR199701557T2 (en) | 1995-06-07 | 2002-06-21 | Ortho Pharmaceutical Corporation | Compounds and peptides that bind to the erythropoietin receptor. |
US5672662A (en) | 1995-07-07 | 1997-09-30 | Shearwater Polymers, Inc. | Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications |
WO1997014740A1 (en) | 1995-10-19 | 1997-04-24 | Receptagen Corporation | Discrete-length polyethylene glycols |
US5639705A (en) * | 1996-01-19 | 1997-06-17 | Arco Chemical Technology, L.P. | Double metal cyanide catalysts and methods for making them |
PT914097E (en) * | 1996-03-12 | 2002-06-28 | Alza Corp | COMPOSITION AND DOSAGE FORM COMPREHENDING OPIOIDE ANTAGONIST |
US5856369A (en) | 1996-07-30 | 1999-01-05 | Osi Specialties, Inc. | Polyethers and polysiloxane copolymers manufactured with double metal cyanide catalysts |
DE19632440A1 (en) | 1996-08-12 | 1998-02-19 | Basf Ag | Easily prepared and separated catalyst giving pure alkoxylation product with narrow molecular weight distribution |
US6214966B1 (en) * | 1996-09-26 | 2001-04-10 | Shearwater Corporation | Soluble, degradable poly(ethylene glycol) derivatives for controllable release of bound molecules into solution |
DE19651551C2 (en) * | 1996-12-11 | 2000-02-03 | Klinge Co Chem Pharm Fab | Opioid antagonist-containing galenic formulation |
US6011008A (en) * | 1997-01-08 | 2000-01-04 | Yissum Research Developement Company Of The Hebrew University Of Jerusalem | Conjugates of biologically active substances |
GB9703044D0 (en) * | 1997-02-14 | 1997-04-02 | Glaxo Group Ltd | Phenyl xanthine esters and amides |
US6565885B1 (en) * | 1997-09-29 | 2003-05-20 | Inhale Therapeutic Systems, Inc. | Methods of spray drying pharmaceutical compositions |
US5972954A (en) * | 1997-11-03 | 1999-10-26 | Arch Development Corporation | Use of methylnaltrexone and related compounds |
AU1825299A (en) * | 1997-12-17 | 1999-07-05 | Enzon, Inc. | Polymeric prodrugs of amino- and hydroxyl-containing bioactive agents |
US6624142B2 (en) * | 1997-12-30 | 2003-09-23 | Enzon, Inc. | Trimethyl lock based tetrapartate prodrugs |
PT1061954E (en) * | 1998-03-12 | 2004-10-29 | Nektar Therapeutics Al Corp | POLY (ETHYLENE GLYCOL) DERIVATIVES WITH NEXT REACTIVE GROUPS |
WO1999050240A1 (en) * | 1998-03-30 | 1999-10-07 | Lg Chemical Ltd. | Polyethoxylated retinamide derivatives and process for preparing the same |
US6703381B1 (en) * | 1998-08-14 | 2004-03-09 | Nobex Corporation | Methods for delivery therapeutic compounds across the blood-brain barrier |
EP0995757A3 (en) | 1998-08-26 | 2002-05-22 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Bivalent inhibitors of the proteasome |
US7060708B2 (en) | 1999-03-10 | 2006-06-13 | New River Pharmaceuticals Inc. | Active agent delivery systems and methods for protecting and administering active agents |
KR100345214B1 (en) | 1999-08-17 | 2002-07-25 | 이강춘 | The nasal transmucosal delivery of peptides conjugated with biocompatible polymers |
US6380405B1 (en) * | 1999-09-13 | 2002-04-30 | Nobex Corporation | Taxane prodrugs |
US6713454B1 (en) * | 1999-09-13 | 2004-03-30 | Nobex Corporation | Prodrugs of etoposide and etoposide analogs |
US6541508B2 (en) * | 1999-09-13 | 2003-04-01 | Nobex Corporation | Taxane prodrugs |
US6451806B2 (en) * | 1999-09-29 | 2002-09-17 | Adolor Corporation | Methods and compositions involving opioids and antagonists thereof |
IL149085A0 (en) * | 1999-10-29 | 2002-11-10 | Inhale Therapeutic Syst | A dry powder composition containing a di or tripeptide |
EP1259562B1 (en) * | 1999-12-22 | 2006-02-15 | Nektar Therapeutics Al, Corporation | Sterically hindered derivatives of water soluble polymers |
US6413507B1 (en) * | 1999-12-23 | 2002-07-02 | Shearwater Corporation | Hydrolytically degradable carbamate derivatives of poly (ethylene glycol) |
WO2001062299A2 (en) | 2000-02-28 | 2001-08-30 | Shearwater Corporation | Water-soluble polymer conjugates of artelinic acid |
AU4743601A (en) * | 2000-03-15 | 2001-09-24 | Wolfgang Sadee | Neutral antagonists and use thereof in treating drug abuse |
WO2003079972A2 (en) | 2002-02-22 | 2003-10-02 | New River Parmaceuticals Inc. | Active agent delivery systems and methods for protecting and administering active agents |
AU2001285311B2 (en) * | 2000-08-29 | 2005-09-15 | Biocon, Ltd | Immunoregulatory compounds, derivatives thereof and their use |
US7829074B2 (en) * | 2001-10-18 | 2010-11-09 | Nektar Therapeutics | Hydroxypatite-targeting poly(ethylene glycol) and related polymers |
US20020182172A1 (en) * | 2000-11-30 | 2002-12-05 | Shearwater Corporation | Water-soluble polymer conjugates of triazine derivatives |
ES2270955T3 (en) * | 2000-12-22 | 2007-04-16 | Smithkline Beecham Plc | MESILATE SALT OF 5- (4- (2- (N-METHYL-N- (2-PIRIDIL) AMINO) ETOXI) BENCIL) THYZOLIDINE-2,4-DIONA. |
JP2004532289A (en) * | 2001-02-20 | 2004-10-21 | エンゾン ファーマシューティカルズ,インコーポレーテッド | Terminally branched polymer linker and polymer conjugate containing the same |
PE20020908A1 (en) * | 2001-03-21 | 2002-10-26 | Cell Therapeutics Inc | RECOMBINANT PRODUCTION OF POLYANIONIC POLYMERS AND USE OF THE SAME |
US6858580B2 (en) * | 2001-06-04 | 2005-02-22 | Nobex Corporation | Mixtures of drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same |
US6828305B2 (en) * | 2001-06-04 | 2004-12-07 | Nobex Corporation | Mixtures of growth hormone drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same |
US6835802B2 (en) * | 2001-06-04 | 2004-12-28 | Nobex Corporation | Methods of synthesizing substantially monodispersed mixtures of polymers having polyethylene glycol moieties |
US6713452B2 (en) * | 2001-06-04 | 2004-03-30 | Nobex Corporation | Mixtures of calcitonin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same |
US6756354B2 (en) * | 2001-09-05 | 2004-06-29 | Deanna Jean Nelson | Therapeutic compositions containing oligo (ethylene glycol)-terminated 1,2-dithiolanes and their conjugates |
CA2463938C (en) * | 2001-10-18 | 2011-08-09 | Nektar Therapeutics Al, Corporation | Polymer conjugates of opioid antagonists |
JP2005508365A (en) * | 2001-10-29 | 2005-03-31 | ネクター セラピューティックス エイエル,コーポレイション | Polymer conjugate of protein kinase C inhibitor |
EP1453545B1 (en) * | 2001-10-30 | 2007-04-18 | Nektar Therapeutics Al, Corporation | Water-soluble polymer conjugates of retinoic acid |
CA2822457C (en) | 2001-12-14 | 2016-03-08 | The University Of Wyoming | Methods and compositions for controlled resease of drugs |
WO2004043396A2 (en) | 2002-11-09 | 2004-05-27 | Nobex Corporation | Modified carbamate-containing prodrugs and methods of synthesizing same |
WO2004082620A2 (en) | 2003-03-13 | 2004-09-30 | Controlled Chemicals, Inc. | Oxycodone conjugates with lower the abuse potential and extended duration of action |
GB0317815D0 (en) * | 2003-07-30 | 2003-09-03 | Amersham Health As | Imaging agents |
CA2534298C (en) | 2003-08-01 | 2013-12-31 | Nobex Corporation | Aryl carbamate oligomers for hydrolyzable prodrugs and prodrugs comprising same |
AU2004293103C1 (en) * | 2003-11-24 | 2010-12-02 | Ratiopharm Gmbh | Glycopegylated erythropoietin |
EP2604282B1 (en) | 2003-12-16 | 2019-06-19 | Nektar Therapeutics | Method for preparing of monodisperse oligo ethylene glycol |
JP5586223B2 (en) * | 2006-04-21 | 2014-09-10 | ネクター セラピューティクス | Stereoselective reduction of morphinone. |
-
2004
- 2004-12-16 EP EP12192296.7A patent/EP2604282B1/en active Active
- 2004-12-16 CA CA2758460A patent/CA2758460C/en active Active
- 2004-12-16 EP EP15156167.7A patent/EP2905033B1/en active Active
- 2004-12-16 PL PL04814802T patent/PL1694363T3/en unknown
- 2004-12-16 CN CN201210398264.8A patent/CN102895666B/en active Active
- 2004-12-16 NZ NZ583573A patent/NZ583573A/en unknown
- 2004-12-16 NZ NZ594834A patent/NZ594834A/en unknown
- 2004-12-16 ES ES12192296T patent/ES2733764T3/en active Active
- 2004-12-16 JP JP2006545533A patent/JP4991312B2/en active Active
- 2004-12-16 CN CN201010150631.3A patent/CN101805343B/en active Active
- 2004-12-16 CN CNA2004800417476A patent/CN1925875A/en active Pending
- 2004-12-16 EP EP04814802.7A patent/EP1694363B1/en active Active
- 2004-12-16 WO PCT/US2004/042661 patent/WO2005058367A2/en active Application Filing
- 2004-12-16 PT PT48148027T patent/PT1694363E/en unknown
- 2004-12-16 ES ES04814802.7T patent/ES2445585T3/en active Active
- 2004-12-16 NZ NZ548529A patent/NZ548529A/en unknown
- 2004-12-16 CA CA2549730A patent/CA2549730C/en active Active
- 2004-12-16 AU AU2004299138A patent/AU2004299138B2/en active Active
- 2004-12-16 RS RS20140185A patent/RS53279B/en unknown
- 2004-12-16 EA EA200601167A patent/EA015333B1/en unknown
- 2004-12-16 ES ES15156167T patent/ES2817799T3/en active Active
- 2004-12-16 DK DK04814802.7T patent/DK1694363T3/en active
- 2004-12-16 EA EA201000994A patent/EA018427B1/en unknown
- 2004-12-16 SI SI200432133T patent/SI1694363T1/en unknown
- 2004-12-16 US US11/015,196 patent/US7786133B2/en active Active
- 2004-12-16 KR KR1020067014260A patent/KR101168620B1/en active IP Right Grant
-
2006
- 2006-06-15 IL IL176317A patent/IL176317A/en active Protection Beyond IP Right Term
- 2006-07-12 ZA ZA200605763A patent/ZA200605763B/en unknown
-
2010
- 2010-06-02 AU AU2010202277A patent/AU2010202277B2/en active Active
- 2010-06-24 US US12/822,935 patent/US8034825B2/en active Active
-
2011
- 2011-01-26 HK HK11100783.8A patent/HK1146645A1/en unknown
-
2013
- 2013-11-19 IL IL229509A patent/IL229509A/en active IP Right Grant
-
2014
- 2014-03-24 CY CY20141100226T patent/CY1114992T1/en unknown
- 2014-04-16 HR HRP20140361TT patent/HRP20140361T1/en unknown
-
2015
- 2015-04-29 HU HUS1500026C patent/HUS1500026I1/en unknown
- 2015-04-29 LU LU92702C patent/LU92702I2/en unknown
- 2015-05-08 NL NL300737C patent/NL300737I2/nl unknown
- 2015-05-15 LT LTPA2015019C patent/LTC1694363I2/en unknown
- 2015-05-18 CY CY2015019C patent/CY2015019I2/en unknown
- 2015-05-19 FR FR15C0037C patent/FR15C0037I2/en active Active
- 2015-11-12 HK HK15111168.6A patent/HK1210418A1/en unknown